Placental stem cell populations
The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
1 .- 52 . (canceled)
53 . An isolated human placental stem cell that is CD34 − or is SH2 + , SH3 + and SH4 + , wherein said placental stem cell is isolated from a human post-partum placenta that has been drained of cord blood and perfused to remove residual blood.
54 . The isolated human placental stem cell of claim 53 , wherein the cell has at least one of the following characteristics: CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SSEA3 − , and SSEA4 − .
55 . The isolated human placental stem cell of claim 53 , wherein the cell has at least the following characteristics: CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SSEA3 − , or SSEA4 − .
56 . The isolated human placental stem cell of claim 53 wherein said cell can differentiate into a cell of a neural, osteogenic or chondrogenic phenotype phenotype.
57 . An isolated cell population comprising the human placental stem cells of claim 53 .
58 . The cell of claim 53 , wherein said cell is isolated from a human placenta that has been drained of cord blood and flushed to remove residual blood.
59 . A composition comprising the isolated placental stem cell of claim 53 or the isolated cell population of claim 58 .
60 . The composition of claim 59 that is a pharmaceutical composition.
61 . An isolated population of CD34 + placental stem cells, wherein said CD34 + placental stem cells have been isolated from a human postpartum placenta that has been drained of cord blood and perfused to remove residual blood.
62 . The isolated population of CD34 + placental stem cells of claim 61 , wherein said cells are in a container.
63 . A composition comprising the isolated population of CD34 + placental stem cells of claim 62 .
64 . The composition of claim 63 that is a pharmaceutical composition.
65 . A method of collecting human CD34 − placental stem cells from post-partum exsanguinated human placenta, said method comprising:
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and
collecting said perfusion solution from said placenta so that said CD34 − placental stem cells are collected.
66 . A method of collecting human CD34 + placental stem cells from post-partum exsanguinated human placenta, said method comprising:
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and
collecting said perfusion solution from said placenta so that said CD34 + placental stem cells are collected.
67 . A method of collecting human placental stem cells from postpartum exsanguinated human placenta, said method comprising:
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and
collecting said perfusion solution from said placenta so that said placental stem cells are collected.
68 . The placental stem cell of claim 53 , wherein said placental stem cell is in a container.
69 . The isolated placental stem cell population of claim 58 , wherein said population is in a container.
70 . The placental stem cell of claim 53 , wherein said placental stem cell comprises a transgene or foreign nucleic acid.
71 . The placental stem cell of claim 70 that is stably transfected.
72 . The placental stem cell of claim 71 , wherein said transgene or foreign nucleic acid encodes a selectable marker.
73 . An isolated population of the placental stem cells of claim 70 .
74 . An isolated population of the placental stem cells of claim 71 , wherein said placental stem cells have been isolated using said selectable marker.
75 . A method of producing a genetically engineered placental stem cell, comprising introducing a transgene or foreign nucleic acid into the placental stem cell of claim 53 .
76 . The method of claim 75 , wherein said introduction comprises transfection, lipofection, homologous recombination, nonhomologous recombination, transformation, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, liposomes, lysosome fusion, synthetic cationic lipids, use of a gene gun or a DNA vector transporter.
77 . The method of claim 75 , wherein said transgene or foreign nucleic acid encodes a selectable marker.
78 . A method of culturing the placental stem cell of claim 53 , comprising expanding said placental stem cell in culture medium under conditions in which differentiation does not occur.
79 . A method of differentiating the placental stem cell of claim 53 , comprising culturing the placental stem cell in contact with one or more factors that cause differentiation.
80 . The method of claim 79 , wherein said one or more factors comprise one or more of Delta-1 polypeptide, human Serrate-1 polypeptide, leukemia inhibitory factor (LIF), stem cell factor (SCF), epithelial growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), keratinocyte growth factor (KGF), TGF-β, interleukin-1 alpha (IL-1α), IL-1β, interferon gamma (IFN-γ), TNF-α, retinoic acid, transferrin, androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, dexamethasone, sodium butyrate, tissue plasminogen activator (tPA), dimethylsulfoxide (DMSO), N-methylformamide (NMF), and/or N,N-dimethylformamide (DMF).
81 . The method of claim 79 , wherein said placental stem cell is differentiated into an adipogenic cell, a cardiac cell, a chondrogenic cell, a neural cell, an osteogenic cell, a pancreatic cell,
82 . A method of using the isolated placental stem cell population of claim 58 to treat a disease, disorder or condition, comprising administering said placental stem cell population to an individual, wherein said disease, disorder or condition is an injury or trauma, or an inborn error of metabolism.
83 . The method of claim 82 , wherein said disease, disorder or condition is myocardial infarction, seizure disorder, multiple sclerosis, stroke, hypotension, cardiac arrest, ischemia, inflammation, age-related loss of cognitive function, radiation damage, cerebral palsy, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Leigh disease, AIDS dementia, memory loss, amyotrophic lateral sclerosis, ischemic renal disease, brain or spinal cord trauma, heart-lung bypass, glaucoma, retinal ischemia, retinal trauma, Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's disease, Hunter's disease, Hurler's syndrome, gangliosidosis, mucopolysaccharidosis, glycogenosis, adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKIJ), porphyrias, maple syrup urine disease, homocystinuria, mucoplysaccharidenosis, chronic granulomatous disease, tyrosinemia or Tay-Sachs disease.
84 . An isolated adherent placental stem cell that is:
CD200 + and HLA-G + ;
CD73 + , CD105 + , and CD200 + ;
CD200 + and OCT-4 + ;
CD73 + , CD105 + and HLA-G + ;
CD73 + and CD105 + and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body; or
OCT-4 + and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies; or any combination thereof.
85 . The isolated stem cell of claim 84 , wherein said CD200 + , HLA-G + stem cell is CD34 − , CD38 − , CD45 − , CD73 + and CD105 + .
86 . The isolated stem cell of claim 84 , wherein said CD73 + , CD105 + , and CD200 + stem cell is CD34 − , CD38 − , CD45 − , and HLA-G + .
87 . The isolated stem cell of claim 84 , wherein said CD200 + , OCT-4 + stem cell is CD34 − , CD38 − , CD45 − , CD73 + , CD105 + and HLA-G + .
88 . The isolated stem cell of claim 84 , wherein said CD73 + , CD105 + and HLA-G + stem cell is CD34 − , CD45 − , OCT-4 + and CD200 + .
89 . The isolated stem cell of claim 84 , wherein said CD73 + and CD105 + stem cell that facilitates the formation of one or more embryoid-like bodies is OCT4 + , CD34 − , CD38 − and CD45 − .
90 . The isolated stem cell of claim 84 , wherein said OCT-4 + and which facilitates the formation of one or more embryoid-like bodies is CD73 + , CD105 + , CD200 + , CD34 − , CD38 − , and CD45 − .
91 . A population of the isolated placental stem cells of claim 84 .
92 . An isolated placental stem cell that expresses one or more genes at a detectably higher level than a bone marrow-derived mesenchymal stem cell,
wherein said one or more genes are ACTG2, ADARB1, AMIGO2, ARTS-1, B4GALT6, BCHE, C11orf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2L1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, IL1A, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A, and
wherein said bone marrow-derived stem cell has undergone a number of passages in culture that is equivalent to the number of passages said placental stem cell has undergone.
93 . A population of isolated placental stem cells, wherein a plurality of said stem cells express one or more genes at a detectably higher level than a population of bone marrow-derived mesenchymal stem cells,
wherein said one or more genes are selected from the group consisting of ACTG2, ADARB1, AMIGO2, ARTS-1, B4GALT6, BCHE, C11orf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, IL1A, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A, and
wherein said bone marrow derived stem cell has undergone a number of passages in culture that is equivalent to the number of passages said placental stem cell has undergone, and
wherein said population of bone marrow-derived mesenchymal stem cells has a number of cells equivalent to that in said population of isolated stem cells.